Merit Medical Beats High End of Expectations, Raises 2026 Revenue and EPS Guidance
MMSI sits 56% above its 52-week low of $59.74.
Summary
Merit posted Q3 revenue of $416.2 million, up 8.4% reported and 9% organic constant currency, with management saying results exceeded the high end of its own expectations. Non-GAAP EPS came in at $1.12, up 22% year over year, and GAAP EPS jumped 51% to $0.70 as GAAP operating margin expanded to 14.1% from 11.1%; third-quarter net income was $42.3 million. The company raised full-year 2026 revenue guidance to $1.635-$1.642 billion and non-GAAP EPS to $4.33-$4.37, up from $4.25-$4.35 previously. Growth was broad: Therapeutic revenue rose 14% reported, led by Endoscopy up 33% and Oncology up 16%, while Foundational grew 6%. Cash generation remains solid with $175.2 million in operating cash flow and $129.5 million of free cash flow year-to-date. The stock sits near its 52-week high of $94.85, so the raised guidance and margin expansion are the key items to confirm on the 4:30 p.m. ET call today.
At the time of this announcement, MMSI was trading at $93.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $59.74 to $94.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.